乳腺浸润性导管癌TOP 2A 基因与相关蛋白及临床病理特征的相关性分析

Correlation analysis between TOP2A gene and breast invasive ductal carcinoma

摘要:

目的 检测乳腺浸润性导管癌拓扑异构酶IIα（TOP 2A ）基因状态变化，探讨其异常率与人类表皮 生长因子受体2（HER2）、雌激素受体（ER）、孕激素受体（PR）、Ki67 蛋白表达及临床病理特征之间的相关性。 方法 筛选乳腺浸润性导管癌患者371 例，通过FISH 检测TOP 2A 基因异常情况，分析TOP 2A 基因状态与ER、 PR、Ki67、HER2 蛋白表达及临床病理特征的关系。结果 371 例乳腺浸润性导管癌患者中TOP 2A 基因异常 率20.49%（76/371），其中基因扩增64 例（17.25%），基因缺失12 例（3.24%），TOP 2A 基因异常与ER、PR 蛋白表达无相关（P >0.05），TOP 2A 基因扩增随着Ki67 与HER2 蛋白表达的增强而增高（P <0.05），TOP 2A 基因异常与年龄、性别、部位及腋窝淋巴结转移差异无相关（P >0.05），与肿瘤大小相关（P <0.05）。结论 TOP 2A 基因及其相关基因蛋白的检测为乳腺浸润性导管癌蒽环类药物的使用提供了参考性依据。

Abstract:

Objective To investigate the correlation between topoisomerase IIα ( TOP2A) gene and breast invasive ductal carcinoma. Methods Totally 371 patients with breast invasive ductal carcinoma were included in this study. Abnormalities of TOP2A gene was determined. Expression of ER, PR, Ki67 and HER2 were measured. Clinical characteristics of patients were recorded. Results The abnormal rate of TOP2A gene was 20.49% (76/371), among which were gene amplification (64, 17.25%), gene deletion (12, 3.24%). No obvious relationship was observed between abnormality of TOP2A and age, gender, site, axillary lymph node metastasis orexpression of ER and PR (P > 0.05). Abnormality of TOP2A was positively associated with tumor size and enhance dexpression of Ki67 and HER2 (P < 0.05). Conclusions Abnormality of TOP2A gene provides fundamental evidence for anthracycline as therapeutic approach for patients with breast invasive ductal carcinoma.